Présentation de l'entreprise

“Iktos was founded in 2016 by Quentin Perron, Nicolas Do Huu, and Yann Gaston-Mathé, with the aim of developing an innovative and user-friendly technology platform for deep-learning based de novo drug design, leveraging a proprietary algorithm developed by Quentin and Nicolas who initially wanted to apply to chemistry the deep learning generative models previously used in fields such as image and natural language processing.

Since that time, academic and industry publications in the field of deep learning for drug design have flourished, however Iktos has retained a pioneering positioning and specific expertise in the field of ligand-based de novo design for multi-parameter optimization.

Our objective is to make our technology accessible to everyone, and to be the first company to release a user-friendly and high-performance de novo design software for multi-parameter optimization, that can be used by any medicinal or computational chemist, whatever their level of expertise in deep learning and computer programming.” from iktos.ai